Novartis Announced New Data From ALITHIOS Open-label Extension Study, Showing First-line Kesimpta (Ofatumumab) Treatment For Up To Six Years Led To Less Disability And Disease Progression In Recently Diagnosed And Treatment-naïve Relapsing Multiple...

諾華公司宣佈來自ALITHIOS開放標籤延長研究的新數據顯示，首線Kesimpta（Ofatumumab）治療長達六年可降低近期診斷和無治療經驗的複發性多發性硬化患者的殘疾和疾病進展。

Benzinga · 09/18 18:02

Novartis Announced New Data From ALITHIOS Open-label Extension Study, Showing First-line Kesimpta (Ofatumumab) Treatment For Up To Six Years Led To Less Disability And Disease Progression In Recently Diagnosed And Treatment-naïve Relapsing Multiple Sclerosis Patients Vs. Those Who Switched From Teriflunomide

諾華公司宣佈來自ALITHIOS開放標籤延長研究的新數據顯示，首線Kesimpta（Ofatumumab）治療長達六年可降低近期診斷和無治療經驗的複發性多發性硬化患者與從Teriflunomide轉換過來的患者相比，殘疾和疾病進展較少。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。